Credit Suisse analyst lifts Lilly rating on Jardiance promise

Some payers have already come out saying they'll need to see new guidelines from medical bodies and more data before they ease access to Eli Lilly and Boehringer Ingelheim's Jardiance, which recently posted a 14% reduction in the combined risk of heart attack, stroke and death from cardiovascular causes in high-risk Type 2 diabetes patients. But Credit Suisse analyst Vamil Divan is optimistic about the med's sales. He's raised his rating on Lilly to outperform, lifting his stock price target to $105--25% above Thursday's closing price of $83.77. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.